Satish Chandrashekaran1, Angela Dispenzieri2, Stephen S Cha3, Cassie C Kennedy4. 1. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55902, USA. Electronic address: Chandrashekaran.Satish@mayo.edu. 2. Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55902, USA. Electronic address: Dispenzieri.Angela@mayo.edu. 3. Department of Biomedical Statistics and Informatics, Mayo Clinic, 200 First St. SW, Rochester, MN 55902, USA. Electronic address: cha@mayo.edu. 4. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55902, USA. Electronic address: kennedy.cassie@mayo.edu.
Abstract
BACKGROUND: POEMS syndrome is a plasma cell disorder manifested by Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes. Pulmonary morbidity includes restriction, decreased diffusing capacity for carbon monoxide (DLCO), respiratory muscle weakness, abnormal imaging, and pulmonary hypertension. Autologous peripheral blood stem cell transplantation (aPBSCT) is an effective treatment for POEMS syndrome. It is unknown if aPBSCT improves pulmonary morbidity. We hypothesize pulmonary morbidity will improve following aPBSCT. METHODS: Retrospective cohort study of POEMS syndrome aPBSCT recipients from 2000 to 2010. Demographic, pulmonary function test (PFT), echocardiogram, cytokine, and imaging data at baseline and after aPBSCT were abstracted. Pre- and post-transplant data were compared using Wilcoxon signed-rank and McNemar's tests. RESULTS: 53 patients met criteria. Median improvements in forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and total lung capacity (TLC) after transplant were 180, 315 and 350 ml respectively (median follow-up of 1.1 years). DLCO, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) improved by a median of 11, 12.5 and 10% predicted respectively. RVSP and chest imaging also improved. Vascular endothelial growth factor and IL-6 decreased by a median of 334 and 2 pg/ml respectively. All comparisons were statistically significant. Longitudinal data demonstrated stability in FEV1, MEP, and TLC and continued improvement in FVC, MIP and DLCO on subsequent PFTs (median follow-up 26.5 months). CONCLUSION: Patients with POEMS syndrome treated with aPBSCT have significant improvement in PFTs, respiratory muscle strength, imaging, and post-transplant IL-6. The improvement in PFTs persists during long-term follow-up.
BACKGROUND:POEMS syndrome is a plasma cell disorder manifested by Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes. Pulmonary morbidity includes restriction, decreased diffusing capacity for carbon monoxide (DLCO), respiratory muscle weakness, abnormal imaging, and pulmonary hypertension. Autologous peripheral blood stem cell transplantation (aPBSCT) is an effective treatment for POEMS syndrome. It is unknown if aPBSCT improves pulmonary morbidity. We hypothesize pulmonary morbidity will improve following aPBSCT. METHODS: Retrospective cohort study of POEMS syndromeaPBSCT recipients from 2000 to 2010. Demographic, pulmonary function test (PFT), echocardiogram, cytokine, and imaging data at baseline and after aPBSCT were abstracted. Pre- and post-transplant data were compared using Wilcoxon signed-rank and McNemar's tests. RESULTS: 53 patients met criteria. Median improvements in forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and total lung capacity (TLC) after transplant were 180, 315 and 350 ml respectively (median follow-up of 1.1 years). DLCO, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) improved by a median of 11, 12.5 and 10% predicted respectively. RVSP and chest imaging also improved. Vascular endothelial growth factor and IL-6 decreased by a median of 334 and 2 pg/ml respectively. All comparisons were statistically significant. Longitudinal data demonstrated stability in FEV1, MEP, and TLC and continued improvement in FVC, MIP and DLCO on subsequent PFTs (median follow-up 26.5 months). CONCLUSION:Patients with POEMS syndrome treated with aPBSCT have significant improvement in PFTs, respiratory muscle strength, imaging, and post-transplant IL-6. The improvement in PFTs persists during long-term follow-up.
Authors: Garvan C Kane; Hilal Maradit-Kremers; Josh P Slusser; Chris G Scott; Robert P Frantz; Michael D McGoon Journal: Chest Date: 2010-11-11 Impact factor: 9.410
Authors: Anita D'Souza; Martha Lacy; Morie Gertz; Shaji Kumar; Francis Buadi; Suzanne Hayman; David Dingli; Steven Zeldenrust; Robert Kyle; Stephen Ansell; David Inwards; Patrick Johnston; Ivana Micallef; Luis Porrata; Mark Litzow; Dennis Gastineau; William Hogan; Angela Dispenzieri Journal: Blood Date: 2012-05-18 Impact factor: 22.113
Authors: P Lesprit; B Godeau; F J Authier; M Soubrier; M Zuber; C Larroche; J P Viard; B Wechsler; R Gherardi Journal: Am J Respir Crit Care Med Date: 1998-03 Impact factor: 21.405
Authors: O Watanabe; I Maruyama; K Arimura; I Kitajima; H Arimura; M Hanatani; K Matsuo; T Arisato; M Osame Journal: Muscle Nerve Date: 1998-11 Impact factor: 3.217
Authors: S Kuwabara; S Misawa; K Kanai; Y Suzuki; Y Kikkawa; S Sawai; T Hattori; M Nishimura; C Nakaseko Journal: Neurology Date: 2008-10-01 Impact factor: 9.910
Authors: Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Shaji K Kumar; Francis Buadi; David Dingli; Mark R Litzow; Dennis A Gastineau; David J Inwards; Michelle A Elliott; Ivana N Micallef; Stephen M Ansell; William J Hogan; Luis F Porrata; Patrick A Johnston; Bekele Afessa; Alan Bryce; Robert A Kyle; Morie A Gertz Journal: Eur J Haematol Date: 2008-01-23 Impact factor: 2.997